There are many ways of achieving the goal of
lowering mutant huntingtin, expected to start new trials soon or already in early trials.
First things first - the news that IONIS - HTTRx
lowers the mutant huntingtin protein is great - but it is not a cure.
Not exact matches
Being able to detect and measure the amount of
mutant huntingtin present in the nervous system will be a valuable way of seeing whether the gene - silencing drug is hitting its target and has the intended effect,
lowering the amount of disease causing mHTT protein.
2015 will see the start of the first human clinical trial of a gene silencing or
huntingtin -
lowering drug, which specifically aims to reduce production of
mutant huntingtin in the brains of HD patients.
The test, called a «single molecule counting assay», combines fluorescent antibodies with a laser detection chamber to count individual molecules of
mutant huntingtin with a very
low detection threshold.
In an announcement likely to stand as one of the biggest breakthroughs in Huntington's disease since the discovery of the HD gene in 1993, Ionis and Roche today announced that the first human trial of a
huntingtin -
lowering drug, IONIS - HTTRx, demonstrates that it reduces
mutant huntingtin in the nervous system, and is safe and well - tolerated.
Some of these approaches to attack
mutant huntingtin also reduce levels of the normal protein, including the Ionis
huntingtin -
lowering drug.
That's not what we expect when patients are given
huntingtin -
lowering drugs, which might produce around 50 - 75 % reductions in the
mutant and healthy protein.
Doing that
lowered levels of the protein for which the gene is a recipe:
mutant huntingtin.
We know that
lowering the level of
mutant huntingtin protein in HD mouse models significantly improves symptoms reminiscent of HD, providing hope that similar treatments in people may be effective.